Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 15, 2015
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study designCaroline A Lee, Meeghan A O'Connor, Tasha K Ritchie, et al.Pharmaceutical Research|October 21, 2011
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancerKunal S Taskar, Vinay Rudraraju, Rajendar K Mittapalli, et al.HIV Medicine|December 26, 2023
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96Shinichi Oka, Vicki Holohan, Takuma Shirasaka, et al.HIV Medicine|November 22, 2022
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trialsParul Patel, Susan L Ford, Mark Baker, et al.Open Forum Infectious Diseases|June 17, 2024
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection AdministrationPaula Teichner, Nadine Chamay, Emilie Elliot, et al.Journal of Clinical Pharmacology|June 6, 2008
PhRMA white paper on ADME pharmacogenomicsJ Andrew Williams, Tommy Andersson, Tommy B Andersson, et al.Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 21, 2023
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic FailureChloe Orkin, Jonathan M Schapiro, Carlo F Perno, et al.AIDS (London, England)|March 17, 2021
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysisAmy G Cutrell, Jonathan M Schapiro, Carlo F Perno, et al.Journal of Pharmaceutical Sciences|February 5, 2021
Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction StudiesMarianne K Vormann, Jelle Vriend, Henriëtte L Lanz, et al.Pageof 6